A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A

The total number of investigational treatment arms will depend on the number of investigational agents evaluated. This study protocol will include a minimum of 1 investigational treatment arms. Refer to Appendix 6, Section 10.6.1. Arm A includes participants treated with MK-2140 and Arm B includes participants treated with MK-3120 plus pembrolizumab.